Yun Wu, M.D., Ph.D.

Peer-Reviewed Articles

1. Ye, Q, Estrella, JS, Kalhor, N, Liu, A, Han, C, Sun, H, Middleton, LP, Chen, H, Albarracin, C, Sahin, AA, Wu, Y, Ding, Q. TRPS1 expression in neuroendocrine neoplasms of breast and other organs. Histopathology 88(2):524-532, 2026. e-Pub 2026. PMID: 41025885.
2. Gan, Q, Ding, Y, Wu, Y, Zhang, Y, Meng, QH, Ding, Q, Lu, H, Shelburne, S, Ehlers II, RA, Han, XY. Infections Due to Corynebacterium kroppenstedtii With Focus on Granulomatous Lobular Mastitis for Tissue Specificity, Pathogenesis, Bacteriologic Workup, and Treatment. Archives of pathology & laboratory medicine 149(9):812-821, 2025. e-Pub 2025. PMID: 39800878.
3. Salem, A, Wu, Y, Ding, Q, Middleton, LP. Impact of NOTCH1 expression in primary breast adenoid cystic carcinoma. Journal of Clinical Pathology 78(8):548-553, 2025. e-Pub 2025. PMID: 38471758.
4. Wang, J, Zhang, Y, Bai, R, Wu, Y, Tong, Z, Liu, AW, Zhang, Y, Wang, H, Wu, X, Cheng, Y, Yang, H, Zhou, Q, Xing, X, Chen, X, Qiu, F, Ma, F. Novel TROP2 antibody–drug conjugates for treatment of HER2-negative metastatic breast cancer patients with brain metastases. ESMO Open 10(5), 2025. e-Pub 2025. PMID: 40359710.
5. Ye, Q, Law, T, Klippel, D, Albarracin, C, Chen, H, Contreras, A, Ding, Q, Huo, L, Khazai, L, Middleton, LP, Resetkova, E, Sahin, AA, Sun, H, Sweeney, K, Symmans, WF, Wu, Y, Yoon, EC, Krishnamurthy, S. Prospective and Retrospective Analysis of Whole-Slide Images of Sentinel and Targeted Lymph Node Frozen Sections in Breast Cancer. Modern Pathology 38(4), 2025. e-Pub 2025. PMID: 39788205.
6. Del Calvo H, Wu Y, Lin HY, Nassif EF, Zarzour MA, Guadagnolo BA, Hunt KK, Bedrosian I, Lillemoe HA. Margin Width and Local Recurrence in Patients with Phyllodes Tumors of the Breast. Ann Surg Oncol 31(12):8048-8056, 2024. e-Pub 2024. PMID: 39085546.
7. Ye Q, Chen H, Han C, Peng Y, Huang X, Sun H, Wu Y, Albarracin CT, Middleton LP, Sahin AA, Huo L, Ding Q. Nuclear staining for pan-Trk by immunohistochemistry is highly specific for secretory carcinoma of breast: pan-Trk in various subtypes of breast carcinoma. J Clin Pathol 77(11):751-755, 2024. e-Pub 2024. PMID: 37586834.
8. Liang, TZ, Ding, Q, Middleton, LP, Wu, Y, Sahin, AA. Characteristics of secretory breast carcinoma with extensive in situ carcinoma components. Human Pathology Reports 37, 2024. e-Pub 2024.
9. Li, L, Wu, Y, Lan, B, Ma, F. Efficacy and safety of first-line regimens for advanced HER2-positive breast cancer. Cancer Innovation 3(4), 2024. e-Pub 2024. PMID: 38948247.
10. Sanchez P, Van Dyke AL, Petkov VI, Yuan Y, Bonds S, Valenzuela C, Tuan AW, Moravec R, Altekruse SF, Singhi AD, Serdy KM, Wu Y, Cress RD, Doherty JA, Mueller L, Hernandez BY, Lynch CF, Tucker TC, Wu XC, Matrisian L, Penberthy L. NCI SEER-Linked Virtual Tissue Repository Pilot. J Natl Cancer Inst Monogr 2024(65):180-190, 2024. e-Pub 2024. PMID: 39102878.
11. Sun, H, Kang, EY, Chen, H, Sweeney, K, Suchko, M, Wu, Y, Wen, J, Krishnamurthy, S, Albarracin, C, Ding, Q, Foo, WC, Sahin, AA. Immunohistochemical assessment of HER2 low breast cancer. Breast Cancer Research and Treatment 205(2):403-411, 2024. e-Pub 2024. PMID: 38441847.
12. Marques-Piubelli, ML, Lyapichev, KA, Fnu, A, Adrada, BE, Stewart, J, Hunt, KK, Clemens, MW, Iyer, S, Wu, Y, El Hussein, S, Xu, J, Ok, CY, Li, S, Pierson, DM, Ferrufino-Schmidt, MC, Nahmod, KA, Yoga, A, Hunsicker, L, Evans, MG, Resetkova, E, Qiu, L, Khanlari, M, Garces, S, Bueso-Ramos, CE, Medeiros, LJ, Miranda, R. The Spectrum of Non-neoplastic Changes Associated with Breast Implants. American Journal of Surgical Pathology 48(6):E43-E64, 2024. e-Pub 2024. PMID: 38451836.
13. Wu, Y, Mo, H, Xu, H, Wang, Y, Wang, J, Ma, F, Xu, B. Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer. Thoracic Cancer 15(12):965-973, 2024. e-Pub 2024. PMID: 38480513.
14. Salem, A, Wu, Y, Albarracin, C, Middleton, LP, Kalhor, N, Peng, Y, Huang, X, Aung, PP, Chen, H, Sahin, AA, Ding, Q. A Comparative Evaluation of TRPS1 and GATA3 in adenoid cystic, secretory, and acinic cell carcinomas of the breast and salivary gland. Human Pathology 145:42-47, 2024. e-Pub 2024. PMID: 38262580.
15. Wang J, Chen H, Koenig J, Wu Y, Bedrosian I, Arun B, Ding Q, Khazai L, Resetkova E, Huo L, Sneige N, Albarracin C. Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers. Breast Cancer Res Treat 203(1):73-83, 2024. e-Pub 2023. PMID: 37751078.
16. Zheng L, Luthra R, Alvarez HA, San Lucas FA, Duose DY, Wistuba II, Fuller GN, Ballester LY, Roy-Chowdhuri S, Sweeney KJ, Rashid A, Yang RK, Chen W, Liu A, Wu Y, Albarracin C, Patel KP, Routbort MJ, Sahin AA, Ding Q, Chen H. Intragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4331 Solid Tumors. Cancers (Basel) 16(1), 2023. e-Pub 2023. PMID: 38201434.
17. Wang M, Ding Q, Gu J, Sfamenos SM, Huo L, Tang Z, Sun H, Robinson M, Tang G, Lim B, Wu Y, Albarracin CT, Sahin AA, Chen H. Breast Cancer With a HER2 FISH Group 2 Result: Should HER2 Tests be Repeated?. Clin Breast Cancer 23(4):415-422, 2023. e-Pub 2023. PMID: 36878823.
18. Zheng C, Wei Y, Zhang P, Xu L, Zhang Z, Lin K, Hou J, Lv X, Ding Y, Chiu Y, Jain A, Islam N, Malovannaya A, Wu Y, Ding F, Xu H, Sun M, Chen X, Chen Y. CRISPR/Cas9 screen uncovers functional translation of cryptic lncRNA-encoded open reading frames in human cancer. J Clin Invest 133(5), 2023. e-Pub 2023. PMID: 36856111.
19. Xu H, Han Y, Wu Y, Wang Y, Wang J, Xu B. Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population-based analysis. Cancer Med 11(23):4501-4512, 2022. e-Pub 2022. PMID: 35598300.
20. Hait NC, Maiti A, Wu R, Andersen VL, Hsu CC, Wu Y, Chapla DG, Takabe K, Rusiniak ME, Bshara W, Zhang J, Moremen KW, Lau JTY. Extracellular sialyltransferase st6gal1 in breast tumor cell growth and invasiveness. Cancer Gene Ther 29(11):1662-1675, 2022. e-Pub 2022. PMID: 35676533.
21. Zhang D, Zhai J, Li L, Wu Y, Ma F, Xu B. Prognostic Factors and a Model for Occult Breast Cancer: A Population-Based Cohort Study. J Clin Med 11(22), 2022. e-Pub 2022. PMID: 36431280.
22. Shen T, Zhao J, Zhao M, Taggart MW, Ramalingam P, Gong Y, Wu Y, Liu H, Zhang J, Resetkova E, Wang WL, Ding Q, Huo L, Yoon E. Unusual Staining of Immunohistochemical Markers PAX8 and CDX2 in Breast Carcinoma: A Potential Diagnostic Pitfall. Hum Pathol 125:35-47, 2022. e-Pub 2022. PMID: 35417734.
23. Zhou P, Chang N, Abraham SC, Albarracin CT, Huo L, Chen H, Ding Q, Resetkova E, Middleton LP, Sahin AA, Bu H, Wu Y. Metastatic non-Hematopoietic Neoplasms to the Breast: A Study of 238 Cases. Hum Pathol 125:59-67, 2022. e-Pub 2022. PMID: 35447141.
24. Yoon EC, Wang G, Parkinson B, Huo L, Peng Y, Wang J, Salisbury T, Wu Y, Chen H, Albarracin CT, Resetkova E, Middleton LP, Krishnamurthy S, Gan Q, Sun H, Huang X, Shen T, Chen W, Parwani AV, Sahin AA, Li Z, Ding Q. TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma. Hum Pathol 125:97-107, 2022. e-Pub 2022. PMID: 35413381.
25. Wang J, Wang WL, Sun H, Huo L, Wu Y, Chen H, Gan Q, Meis JM, Maloney N, Lazar AJ, Yoon EC, Albarracin CT, Krishnamurthy S, Middleton LP, Resetkova E, Yu W, Tan D, Lu W, Solis Soto LM, Wang S, Wistuba II, Parwani AV, Prieto VG, Sahin AA, Li Z, Ding Q. Expression of TRPS1 in phyllodes tumor and sarcoma of the breast. Hum Pathol 121:73-80, 2022. e-Pub 2022. PMID: 35063444.
26. McLemore LE, Albarracin CT, Gruschkus SK, Bassett RL, Wu Y, Dhamne S, Yim I, Lin K, Bedrosian I, Sneige N, Chen H. HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines. Breast Cancer Res Treat 187(1):95-104, 2021. e-Pub 2021. PMID: 33813685.
27. Chou PC, Choi HH, Huang Y, Fuentes-Mattei E, Velazquez-Torres G, Zhang F, Phan L, Lee J, Shi Y, Bankson JA, Wu Y, Wang H, Zhao R, Yeung SJ, Lee MH. Impact of diabetes on promoting the growth of breast cancer. Cancer Commun (Lond) 41(5):414-431, 2021. e-Pub 2021. PMID: 33609419.
28. Yang L, Roy M, Lin H, Shen Y, Albarracin C, Huo L, Chen H, Wei B, Bedrosian I, Bu H, Wu Y. Validation of prognostic significance of the proposed uniform classification framework in neuroendocrine neoplasms of the breast. Breast Cancer Res Treat 186(2):403-415, 2021. e-Pub 2021. PMID: 33528758.
29. Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, Soto LMS, Jiang M, Raso MG, Wang S, Bell D, Liu J, Wang H, Tan D, Torres-Cabala C, Gan Q, Wu Y, Albarracin C, Hung MC, Meric-Bernstam F, Wistuba II, Prieto VG, Sahin AA, Ding Q. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol 34(4):710-719, 2021. e-Pub 2021. PMID: 33011748.
30. Huang X, Ding Q, Guo H, Gong Y, Zhao J, Zhao M, Sui D, Wu Y, Chen H, Liu H, Zhang J, Resetkova E, Moulder SL, Wang WL, Huo L. Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma. Hum Pathol 108:42-50, 2021. e-Pub 2021. PMID: 33221342.
31. Hou J, Zhao R, Xia W, Chang CW, You Y, Hsu JM, Nie L, Chen Y, Wang YC, Liu C, Wang WJ, Wu Y, Ke B, Hsu JL, Huang K, Ye Z, Yang Y, Xia X, Li Y, Li CW, Shao B, Tainer JA, Hung MC. Author Correction: PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol 22(11):1396, 2020. e-Pub 2020. PMID: 33033376.
32. Hou J, Zhao R, Xia W, Chang CW, You Y, Hsu JM, Nie L, Chen Y, Wang YC, Liu C, Wang WJ, Wu Y, Ke B, Hsu JL, Huang K, Ye Z, Yang Y, Xia X, Li Y, Li CW, Shao B, Tainer JA, Hung MC. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol 22(10):1264-1275, 2020. e-Pub 2020. PMID: 32929201.
33. Kim JM, Eng RK, Shehabeldin AN, Ge Y, Schwartz MR, Wu Y, Ro JY. Desmoplastic Small Round Cell Tumor with an Unusual Site and Age Presentation: A Case Report and Literature Review. Surgical Case Reports 3(8):2-5, 2020. e-Pub 2020.
34. Guo H, Ding Q, Gong Y, Gilcrease MZ, Zhao M, Zhao J, Sui D, Wu Y, Chen H, Liu H, Zhang J, Resetkova E, Moulder SL, Wang WL, Huo L. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors. Breast Cancer Res 22(1):69, 2020. e-Pub 2020. PMID: 32576238.
35. Richards D, Ayala AA, Wu Y, Middleton LP. Carcinoma In Situ Involving Sclerosing Adenosis on Core Biopsy: Diagnostic Pearls to Aid the Practicing Clinician and Avoid Overtreatment. Oncol Ther 8(1):81-89, 2020. e-Pub 2020. PMID: 32700071.
36. Lyapichev KA, Piña-Oviedo S, Medeiros LJ, Evans MG, Liu H, Miranda AR, Hunt KK, Clemens MW, Stewart JM, Amin MB, Quesada AE, Chai SM, Di Napoli A, Yoga A, Dave SK, Wistuba II, Wu Y, Bueso-Ramos CE, Schlette EJ, Ferrufino-Schmidt MC, Loghavi S, Khoury JD, Young KH, Miranda RN. A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma. Mod Pathol 33(3):367-379, 2020. e-Pub 2020. PMID: 31383966.
37. Krishnamurthy S, Sabir S, Ban K, Wu Y, Sheth R, Tam A, Meric-Bernstam F, Shaw K, Mills G, Bassett R, Hamilton S, Hicks M, Gupta S. Comparison of Real-Time Fluorescence Confocal Digital Microscopy With Hematoxylin-Eosin-Stained Sections of Core-Needle Biopsy Specimens. JAMA Netw Open 3(3):e200476, 2020. e-Pub 2020. PMID: 32134465.
38. Waks AG, Stover DG, Guerriero JL, Dillon D, Barry WT, Gjini E, Hartl C, Lo W, Savoie J, Brock J, Wesolowski R, Li Z, Damicis A, Philips AV, Wu Y, Yang F, Sullivan A, Danaher P, Brauer HA, Osmani W, Lipschitz M, Hoadley KA, Goldberg M, Perou CM, Rodig S, Winer EP, Krop IE, Mittendorf EA, Tolaney SM. The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. Clin Cancer Res 25(15):4644-4655, 2019. e-Pub 2019. PMID: 31061067.
39. Echeverria GV, Ge Z, Seth S, Zhang X, Jeter-Jones S, Zhou X, Cai S, Tu Y, McCoy A, Peoples M, Sun Y, Qiu H, Chang Q, Bristow C, Carugo A, Shao J, Ma X, Harris A, Mundi P, Lau R, Ramamoorthy V, Wu Y, Alvarez MJ, Califano A, Moulder SL, Symmans WF, Marszalek JR, Heffernan TP, Chang JT, Piwnica-Worms H. Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Sci Transl Med 11(488), 2019. e-Pub 2019. PMID: 30996079.
40. Park MK, Yao Y, Xia W, Setijono SR, Kim JH, Vila IK, Chiu HH, Wu Y, Billalabeitia EG, Lee MG, Kalb RG, Hung MC, Pandolfi PP, Song SJ, Song MS. PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression. Nat Commun 10(1):636, 2019. e-Pub 2019. PMID: 30733438.
41. Jerevall PL, Brock J, Palazzo J, Wieczorek T, Misialek M, Guidi AJ, Wu Y, Erlander MG, Zhang Y, Schnabel CA, Goss PE, Horick N, Sgroi DC. Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score. Breast Cancer Res Treat 173(2):375-383, 2019. e-Pub 2019. PMID: 30350269.
42. Wang M, Liang L, Lei X, Multani A, Meric-Bernstam F, Tripathy D, Wu Y, Chen H, Zhang H. Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers. Ann Diagn Pathol 35:69-76, 2018. e-Pub 2018. PMID: 29843069.
43. Ding Q, Wang Y, Zuo Z, Gong Y, Krishnamurthy S, Li CW, Lai YJ, Wei W, Wang J, Manyam GC, Diao L, Zhang X, Lin F, Symmans WF, Sun L, Liu CG, Liu X, Debeb BG, Ueno NT, Harano K, Alvarez RH, Wu Y, Cristofanilli M, Huo L. Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. Hum Pathol 77:121-129, 2018. e-Pub 2018. PMID: 29689244.
44. Li CW, Lim SO, Chung EM, Kim YS, Park AH, Yao J, Cha JH, Xia W, Chan LC, Kim T, Chang SS, Lee HH, Chou CK, Liu YL, Yeh HC, Perillo EP, Dunn AK, Kuo CW, Khoo KH, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Huang TH, Sahin AA, Hortobagyi GN, Yoo SS, Hung MC. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell 33(2):187-201.e10, 2018. e-Pub 2018. PMID: 29438695.
45. Wan L, Xu K, Wei Y, Zhang J, Han T, Fry C, Zhang Z, Wang YV, Huang L, Yuan M, Xia W, Chang WC, Huang WC, Liu CL, Chang YC, Liu J, Wu Y, Jin VX, Dai X, Guo J, Liu J, Jiang S, Li J, Asara JM, Brown M, Hung MC, Wei W. Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function. Mol Cell 69(2):279-291.e5, 2018. e-Pub 2018. PMID: 29351847.
46. Powell E, Shao J, Picon HM, Bristow C, Ge Z, Peoples M, Robinson F, Jeter-Jones SL, Schlosberg C, Grzeskowiak CL, Yang F, Wu Y, Wistuba I, Moulder SL, Symmans WF, Scott KL, Edwards JR, Liang H, Heffernan TP, Piwnica-Worms H. A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasis. NPJ Breast Cancer 4:9, 2018. e-Pub 2018. PMID: 29736411.
47. Chang SS, Yamaguchi H, Xia W, Lim SO, Khotskaya Y, Wu Y, Chang WC, Liu Q, Hung MC. Aurora A kinase activates YAP signaling in triple-negative breast cancer. Oncogene 36(9):1265-1275, 2017. e-Pub 2017. PMID: 27593935.
48. Chen H, Singh RR, Lu X, Huo L, Yao H, Aldape K, Abraham R, Virani S, Mehrotra M, Mishra BM, Bousamra A, Albarracin C, Wu Y, Roy-Chowdhuri S, Kanagal-Shamanna R, Routbort MJ, Medeiros LJ, Patel KP, Broaddus R, Sahin A, Luthra R. Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. Oncotarget 8(7):10845-10857, 2017. e-Pub 2017. PMID: 28125801.
49. Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, Chang SS, Lin WC, Hsu JM, Hsu YH, Kim T, Chang WC, Hsu JL, Yamaguchi H, Ding Q, Wang Y, Yang Y, Chen CH, Sahin AA, Yu D, Hortobagyi GN, Hung MC. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell 30(6):925-939, 2016. e-Pub 2016. PMID: 27866850.
50. Castaneda CA, Mittendorf E, Casavilca S, Wu Y, Castillo M, Arboleda P, Nunez T, Guerra H, Barrionuevo C, Dolores-Cerna K, Belmar-Lopez C, Abugattas J, Calderon G, De La Cruz M, Cotrina M, Dunstan J, Gomez HL, Vidaurre T. Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy. World J Clin Oncol 7(5):387-394, 2016. e-Pub 2016. PMID: 27777881.
51. Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Ding Q, Wang Y, Yao J, Lee CC, Wu HJ, Sahin AA, Allison JP, Yu D, Hortobagyi GN, Hung MC. Glycosylation and stabilization of programmed death ligand-1 suppresses T cell activity. Nat Commun 7:12632, 2016. e-Pub 2016. PMID: 27572267.
52. Swisher S, Wu Y, Castaneda Altamirano C, Lyons GR, Yang F, Tapia C, Wang X, Bassett Jr RL, Casavilca Zambrano S, Castillo M, Sahin AA, Mittendorf EA. Interobserver agreement between pathologists assessing tumor-infiltrating lymphocytes (TILs) in breast cancer using methology proposed by the International TILs Working Group. Annals of Surgical Oncology, 2016. e-Pub 2016. PMID: 26965699.
53. Huo L, Wang Y, Gong Y, Krishnamurthy S, Wang J, Diao L, Liu C, Liu X, Lin F, Symmans WF, Wei W, Ueno N, Harano K Debeb B, Wu Y, Reuben J, Cristofanilli M, Zuo Z, Zhang X, Sun L, Alvarez R, Fouad T. MicroRNA Expresssion Profiling Identifies Decreased Expression of miR-205 in inflammatory Breast Cancer. Mod Pathol, 2016. e-Pub 2016. PMID: 26916073.
54. Li CW, Xia W, Lim SO, Hsu JL, Huo L, Wu Y, Li LY, Lai CC, Chang SS, Hsu YH, Sun HL, Kim J, Yamaguchi H, Lee DF, Wang H, Wang Y, Chou CK, Hsu JM, Lai YJ, LaBaff AM, Ding Q, Ko HW, Tsai FJ, Tsai CH, Hortobagyi GN, Hung MC. AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. Cancer Res 76(6):1451-62, 2016. e-Pub 2016. PMID: 26759241.
55. Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard P, Lee IV GR, Chen MK, Nakai K, Shu MC, Chen CT, Sun Y, Wu Y, Chang WC, Huang WC, Liu CL, Chang YC, Chen CH, Park M, Jones P, Hortobagyi GN, Hung MC. Blocking c-Met-mediated PARP1 phosphorylation enhances PARP inhibitor response. Nature Medicine, 2016. e-Pub 2016. PMID: 26779812.
56. Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, Wu Y, Chang WC, Huang WC, Liu CL, Chang YC, Chen CH, Park M, Jones P, Hortobagyi GN, Hung MC. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med 22(2):194-201, 2016. e-Pub 2016. PMID: 26779812.
57. Lim SO, Li CW, Xia W, Lee HH, Chang SS, Shen J, Hsu JL, Raftery D, Djukovic D, Gu H, Chang WC, Wang HL, Chen ML, Huo L, Chen CH, Wu Y, Sahin A, Hanash SM, Hortobagyi GN, Hung MC. EGFR signaling enhances aerobic glycolysis in triple negative breast cancer cells to promote tumor growth and immune escape. Cancer Res. e-Pub 2016. PMID: 26759242.
58. Wang J, Kalhor N, Hu J, Wang B, Chu H, Zhang B, Guan Y, Wu Y. Pretreatment Neutrophil to Lymphocyte Ratio Is Associated with Poor Survival in Patients with Stage I-III Non-Small Cell Lung Cancer. PLoS One 11(10):e0163397, 2016. e-Pub 2016. PMID: 27695079.
59. Huo L, Gong Y, Guo M, Gilcrease MZ, Wu Y, Zhang H, Zhang J, Resetkova E, Hunt KK, Deavers MT. GATA-3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry. Histopathology 67(2):245-54, 2015. e-Pub 2015. PMID: 25564996.
60. Phan L, Chou PC, Velazquez-Torres G, Samudio I, Parreno K, Huang Y, Tseng C, Vu T, Gully C, Su CH, Wang E, Chen J, Choi HH, Fuentes-Mattei E, Shin JH, Shiang C, Grabiner B, Blonska M, Skerl S, Shao Y, Cody D, Delacerda J, Kingsley C, Webb D, Carlock C, Zhou Z, Hsieh YC, Lee J, Elliott A, Ramirez M, Bankson J, Hazle J, Wang Y, Li L, Weng S, Rizk N, Wen YY, Lin X, Wang H, Wang H, Zhang A, Xia X, Wu Y, Habra M, Yang W, Pusztai L, Yeung SC, Lee MH. The cell cycle regulator 14-3-3σ opposes and reverses cancer metabolic reprogramming. Nat Commun 6:7530, 2015. e-Pub 2015. PMID: 26179207.
61. Xiang DB, Wei B, Abraham SC, Huo L, Albarracin CT, Zhang H, Babiera G, Caudle AS, Akay CL, Rao P, Zhao YJ, Lu X, Wu Y. Molecular cytogenetic characterization of mammary neuroendocrine carcinoma. Hum Pathol 45(9):1951-6, 2014. e-Pub 2014. PMID: 25074542.
62. Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Wang MY, Li CW, Shen J, Chen MK, Sahin AA, Sood A, Mills GB, Yu D, Hortobagyi GN, Hung MC. Definition of PKC-α, CDK6, and MET as Therapeutic Targets in Triple-Negative Breast Cancer. Cancer Res 74(17):4822-35, 2014. e-Pub 2014. PMID: 24970481.
63. Dokmanovic M, Wu Y, Shen Y, Chen J, Hirsch DS, Wu WJ. Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition. Cancer Biol Ther 15(8):1029-41, 2014. e-Pub 2014. PMID: 24835103.
64. Park YM, Wu Y, Wei W, Yang W. Primary Neuroendocrine Carcinoma of the Breast: Clinical, Imaging, and Histopathologic Features. American Journal of Roentgenology, 2014. e-Pub 2014. PMID: 25055297.
65. Park YM, Wu Y, Wei W, Yang WT. Primary neuroendocrine carcinoma of the breast: clinical, imaging, and histologic features. AJR Am J Roentgenol 203(2):W221-30, 2014. e-Pub 2014. PMID: 25055297.
66. Fuentes-Mattei E, Velazquez-Torres G, Phan L, Zhang F, Chou PC, Shin JH, Choi HH, Chen JS, Zhao R, Chen J, Gully C, Carlock C, Qi Y, Zhang Y, Wu Y, Esteva FJ, Luo Y, McKeehan WL, Ensor J, Hortobagyi GN, Pusztai L, Fraser Symmans W, Lee MH, Yeung SC. Obesity Induces Transcriptomic Changes Enhancing Cancer Hallmarks of Estrogen Receptor-Positive Breast Cancer. J Natl Cancer Inst 106(7), 2014. e-Pub 2014. PMID: 24957076.
67. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. PD-L1 Expression in Triple Negative Breast Cancer. Cancer Immunol Res 2(4):361-70, 2014. e-Pub 2014. PMID: 24764583.
68. Gong Y, Wei W, Wu Y, Ueno NT, Huo L. Expression of androgen receptor in inflammatory breast cancer and its clinical relevance. Cancer. e-Pub 2014. PMID: 24634055.
69. Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, Symmans WF, Miller VA, Stephens P, Pusztai L. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. Oncologist 19(5):453-8, 2014. e-Pub 2014. PMID: 24710307.
70. Wang J, Mittendorf EA, Sahin AA, Yi M, Caudle A, Hunt KK, Wu Y. Outcomes of Sentinel Lymph Node Dissection Alone vs. Axillary Lymph Node Dissection in Early Stage Invasive Lobular Carcinoma: A Retrospective Study of the Surveillance, Epidemiology and End Results (SEER) Database. PLoS One 9(2):e89778, 2014. e-Pub 2014. PMID: 24587029.
71. Wang J, Wei B, Albarracin CT, Hu J, Abraham SC, Wu Y. Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database. BMC Cancer 14:147, 2014. e-Pub 2014. PMID: 24589259.
72. Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez-Macgregor M, Smart M, Gonzalez-Angulo AM. Mesothelin Expression and Survival Outcomes in Triple Receptor Negative Breast Cancer. Clin Breast Cancer 13(5):378-84, 2013. e-Pub 2013. PMID: 23810431.
73. Chen JQ, Bao Y, Lee J, Murray JL, Litton JK, Xiao L, Zhou R, Wu Y, Shen XY, Zhang H, Sahin AA, Katz RL, Bondy ML, Berinstein NL, Hortobagyi GN, Radvanyi LG. Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer. Ann Oncol 24(10):2534-42, 2013. e-Pub 2013. PMID: 23729783.
74. Wang J, Li D, Wang B, Wu Y. Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 141(2):213-24, 2013. e-Pub 2013. PMID: 24036660.
75. Sharaf Aldeen B, Feng J, Wu Y, Nassar Warzecha H. Molecular subtypes of ductal carcinoma in situ in African American and Caucasian American women: distribution and correlation with pathological features and outcome. Cancer Epidemiol 37(4):474-8, 2013. e-Pub 2013. PMID: 23639792.
76. Huang TH, Huo L, Wang YN, Xia W, Wei Y, Chang SS, Chang WC, Fang YF, Chen CT, Lang JY, Tu C, Wang Y, Hsu MC, Kuo HP, Ko HW, Shen J, Lee HH, Lee PC, Wu Y, Chen CH, Hung MC. Epidermal Growth Factor Receptor Potentiates MCM7-Mediated DNA Replication through Tyrosine Phosphorylation of Lyn Kinase in Human Cancers. Cancer Cell 23(6):796-810, 2013. e-Pub 2013. PMID: 23764002.
77. Nayak A, Wu Y, Gilcrease MZ. Primary squamous cell carcinoma of the breast: predictors of locoregional recurrence and overall survival. Am J Surg Pathol 37(6):867-73, 2013. e-Pub 2013. PMID: 23629447.
78. Chawla A, Alatrash G, Wu Y, Mittendorf EA. Immune aspects of the breast tumor microenvironment. Breast Cancer Manag 2(3):231-244, 2013. e-Pub 2013. PMID: 24516507.
79. Shen J, Xia W, Khotskaya YB, Huo L, Nakanishi K, Lim SO, Du Y, Wang Y, Chang WC, Chen CH, Hsu JL, Wu Y, Lam YC, James BP, Liu X, Liu CG, Patel DJ, Hung MC. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 497(7449):383-387, 2013. e-Pub 2013. PMID: 23636329.
80. Desai S, Liu Z, Yao J, Patel N, Chen J, Wu Y, Ahn EE, Fodstad O, Tan M. Heat shock factor 1 (HSF1) controls chemoresistance and autophagy through transcriptional regulation of autophagy-related protein 7 (ATG7). J Biol Chem 288(13):9165-76, 2013. e-Pub 2013. PMID: 23386620.
81. Bayraktar S, Gutierrez Barrera AM, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y, Symmans F, Arun B. USP-11 as a Predictive and Prognostic Factor Following Neoadjuvant Therapy in Women with Breast Cancer. Cancer J 19(1):10-17, 2013. e-Pub 2013. PMID: 23337751.
82. Huo L, Zhang J, Gilcrease MZ, Gong Y, Wu Y, Zhang H, Resetkova E, Hunt KK, Deavers MT. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer. Histopathology 62(2):267-74, 2013. e-Pub 2013. PMID: 22963676.
83. Alatrash G, Mittendorf EA, Sergeeva A, Sukhumalchandra P, Qiao N, Zhang M, St John LS, Ruisaard K, Haugen CE, Al-Atrache Z, Jakher H, Philips AV, Ding X, Chen JQ, Wu Y, Patenia RS, Bernatchez C, Vence LM, Radvanyi LG, Hwu P, Clise-Dwyer K, Ma Q, Lu S, Molldrem JJ. Broad Cross-Presentation of the Hematopoietically Derived PR1 Antigen on Solid Tumors Leads to Susceptibility to PR1-Targeted Immunotherapy. J Immunol 189(11):5476-84, 2012. e-Pub 2012. PMID: 23105141.
84. Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer. Clin Cancer Res 18(20):5816-28, 2012. e-Pub 2012. PMID: 22932669.
85. Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Wu Y, Gilcrease MZ, Bedrosian I, Dawood S, Arun B, Albarracin CT. Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast. Am J Surg Pathol 36(9):1353-8, 2012. e-Pub 2012. PMID: 22895267.
86. Delpech Y, Wu Y, Hess KR, Hsu L, Ayers M, Natowicz R, Coutant C, Rouzier R, Barranger E, Hortobagyi GN, Mauro D, Pusztai L. Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat 135(2):619-27, 2012. e-Pub 2012. PMID: 22890751.
87. Mittendorf EA, Alatrash G, Qiao N, Wu Y, Sukhumalchandra P, St John LS, Philips AV, Xiao H, Zhang M, Ruisaard K, Clise-Dwyer K, Lu S, Molldrem JJ. Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response. Cancer Res 72(13):3153-62, 2012. e-Pub 2012. PMID: 22564522.
88. Kundu UR, Guo M, Landon G, Wu Y, Sneige N, Gong Y. Fine-needle aspiration cytology of sclerosing adenosis of the breast: a retrospective review of cytologic features in conjunction with corresponding histologic features and radiologic findings. Am J Clin Pathol 138(1):96-102, 2012. e-Pub 2012. PMID: 22706864.
89. Wu Y, Mittendorf EA, Kelten C, Tucker SL, Wei W, Middleton LP, Broglio K, Buchholz TA, Hunt KK, Sahin AA. Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer. Cancer 118(6):1507-14, 2012. e-Pub 2012. PMID: 22009292.
90. Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, Li CW, Hsu JL, Miller SA, Wang X, Lee DF, Hsu JM, Huo L, Labaff AM, Liu D, Huang TH, Lai CC, Tsai FJ, Chang WC, Chen CH, Wu TT, Buttar NS, Wang KK, Wu Y, Wang H, Ajani J, Hung MC. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell 21(3):374-87, 2012. e-Pub 2012. PMID: 22439934.
91. Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, Chao CH, Yamaguchi H, Yang NK, Ding Q, Wang Y, Lai YJ, LaBaff AM, Wu TJ, Lin BR, Yang MH, Hortobagyi GN, Hung MC. Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1. Cancer Res 72(5):1290-300, 2012. e-Pub 2012. PMID: 22253230.
92. Le XF, Almeida MI, Mao W, Spizzo R, Rossi S, Nicoloso MS, Zhang S, Wu Y, Calin GA, Bast RC. Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer. PLoS One 7(7):e41170, 2012. e-Pub 2012. PMID: 22829924.
93. Hatzis C, Sun H, Yao H, Hubbard RE, Meric-Bernstam F, Babiera GV, Wu Y, Pusztai L, Symmans WF. Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers. J Natl Cancer Inst 103(24):1871-83, 2011. e-Pub 2011. PMID: 22034635.
94. Wahbah MM, Gilcrease MZ, Wu Y. Lipomatous variant of myofibroblastoma with epithelioid features: a rare and diagnostically challenging breast lesion. Ann Diagn Pathol 15(6):454-8, 2011. e-Pub 2011. PMID: 21036082.
95. Perry KD, Reynolds C, Rosen DG, Edgerton ME, T Albarracin C, Gilcrease MZ, Sahin AA, Abraham SC, Wu Y. Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma. Histopathology 59(4):619-30, 2011. e-Pub 2011. PMID: 22014043.
96. Tian Z, Wei B, Tang F, Wei W, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Middleton L, Sahin A, Xing Y, Hunt KK, Chen J, Bu H, Rashid A, Abraham SC, Wu Y. Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. Hum Pathol 42(8):1169-77, 2011. e-Pub 2011. PMID: 21334720.
97. Zhao Y, Liu H, Liu Z, Ding Y, Ledoux SP, Wilson GL, Voellmy R, Lin Y, Lin W, Nahta R, Liu B, Fodstad O, Chen J, Wu Y, Price JE, Tan M. Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism. Cancer Res 71(13):4585-4597, 2011. e-Pub 2011. PMID: 21498634.
98. Tang F, Wei B, Tian Z, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Zhang H, Sahin A, Chen J, Bu H, Abraham S, Wu Y. Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges. Histopathology 59(1):106-15, 2011. e-Pub 2011. PMID: 21668471.
99. Adejolu M, Wu Y, Santiago L, Yang WT. Adenomyoepithelial tumors of the breast: imaging findings with histopathologic correlation. AJR Am J Roentgenol 197(1):W184-90, 2011. e-Pub 2011. PMID: 21700984.
100. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305(18):1873-81, 2011. e-Pub 2011. PMID: 21558518.
101. Huo L, Bell D, Qiu H, Sahin A, Wu Y, Sneige N. Paneth cell-like eosinophilic cytoplasmic granules in breast carcinoma. Ann Diagn Pathol 15(2):84-92, 2011. e-Pub 2011. PMID: 21163678.
102. Chen JQ, Bao Y, Litton J, Xiao L, Zhang HZ, Warneke CL, Wu Y, Shen X, Wu S, Katz RL, Sahin A, Bondy M, Murray JL, Radvanyi L. Expression and relevance of TRPS-1: a new GATA transcription factor in breast cancer. Horm Cancer 2(2):132-143, 2011. e-Pub 2011. PMID: 21761336.
103. Wei B, Ding T, Xing Y, Wei W, Tian Z, Tang F, Abraham S, Nayeemuddin K, Hunt K, Wu Y. Invasive Neuroendocrine Carcinoma of the Breast: A Distinctive Subtype of Aggressive Mammary Carcinoma. Cancer 116(19):4463-73, 2010. e-Pub 2010. PMID: 20572042.
104. Morkowski JJ, Nguyen CV, Lin P, Farr M, Abraham SC, Gilcrease MZ, Moran CA, Wu Y. Rosai-Dorfman disease confined to the breast. Ann Diagn Pathol 14(2):81-7, 2010. e-Pub 2010. PMID: 20227012.
105. Chen JQ, Litton J, Xiao L, Zhang HZ, Warneke CL, Wu Y, Shen X, Wu S, Sahin A, Katz R, Bondy M, Hortobagyi G, Berinstein NL, Murray JL, Radvanyi L. Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancer. Horm Cancer 1(1):21-23, 2010. e-Pub 2010. PMID: 21761348.
106. Lee YS, Gilcrease MZ, Wu Y, Yang W. Myofibroblastoma of the breast: Imaging features. Eur J Radiol 73(1):13-15, 2010. e-Pub 2010.
107. Chang KN, Carkaci S, Wu Y, Yang W. Xanthogranuloma of the Breast. Eur J Radiol Extra 75:e17-19, 2010. e-Pub 2010.
108. Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H, Eksambi S, Hortobagyi GN, Baselga J, Gonzalez-Angulo AM. Loss of HER2 amplification following Trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 15(23):7381-8, 2009. e-Pub 2009. PMID: 19920100.
109. Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, Feig B, Zhang W, Pusztai L, Symmans WF, Wu Y, Arlinghaus RB. Inhibition of Lipocalin 2 Impairs Breast Tumorigenesis and Metastasis. Cancer Res 69(22):8579-84, 2009. e-Pub 2009. PMID: 19887608.
110. Downs-Kelly E, Nayeemuddin KM, Albarracin C, Wu Y, Hunt KK, Gilcrease MZ. Matrix-producing carcinoma of the breast: an aggressive subtype of metaplastic carcinoma. Am J Surg Pathol 33(4):534-41, 2009. e-Pub 2009. PMID: 19047898.
111. Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A, Albarracin CT. Loss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol 16(6):530-4, 2008. e-Pub 2008. PMID: 18776816.
112. Leng X, Lin H, Ding T, Wang Y, Wu Y, Klumpp S, Sun T, Zhou Y, Monaco P, Belmont J, Aderem A, Akira S, Strong R, Arlinghaus R. Lipocalin 2 is required for BCR-ABL-induced tumorigenesis. Oncogene 27(47):6110-19, 2008. e-Pub 2008. PMID: 18663364.
113. Nicolas MM, Wu Y, Middleton LP, Gilcrease MZ. Loss of myoepithelium is variable in solid papillary carcinoma. Histopathology 51(5):657-65, 2007. e-Pub 2007. PMID: 17927587.
114. He J, Pan Y, Hu J, Albarracin C, Wu Y, Dai JL. Profile of Ets gene expression in human breast carcinoma. Cancer Biol Ther 6(1):76-82, 2007. e-Pub 2007. PMID: 17172821.
115. Anderson K, Hess KR, Kapoor M, Tirrell S, Courtemanche J, Wang B, Wu Y, Gong Y, Hortobagyi GN, Symmans WF, Pusztai L. Reproducibility of gene expression signature - based predictions in replicate experiments. Clin Cancer Res 12(6):1721-7, 2006. e-Pub 2006. PMID: 16551855.
116. Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rozier R, Dunmire V, Stec J, Valero V, Sneige N, Albarracin C, Wu Y, Ross JS, Wagner P, Theriault RL, Arun B, Kuerer H, Hess, KR, Zhang W, Hortobagyi GN, Pusztai L. A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocr Relat Cancer 12(4):1059-60, 2005. e-Pub 2005. PMID: 16322343.
117. Wu Y, Soslow RA, Marshall DS, Leitao M, Chen B. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Gynecol Oncol 95(3):570-5, 2004. e-Pub 2004. PMID: 15581965.
118. Hawk N, Sun T, Xie S, Wang Y, Wu Y, Liu J, Arlinghaus RB. Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354. Cancer Res 62(2):386-90, 2002. e-Pub 2002. PMID: 11809685.
119. Abe JI, Che W, Yoshizumi M, Huang Q, Glassman M, Ohta S, Wu Y, Arlinghaus R, Berk BC. Bcr in vascular smooth muscle cells involvement of Ras and Raf-1 activation by Bcr. Ann N Y Acad Sci 947:341-3, 2001. e-Pub 2001. PMID: 11795286.
120. Che W, Abe J, Yoshizumi M, Huang Q, Glassman M, Ohta S, Melaragno MG, Poppa V, Yan C, Lerner-Marmarosh N, Zhang C, Wu Y, Arlinghaus R, Berk BC. p160 Bcr mediates platelet-derived growth factor activation of extracellular signal-regulated kinase in vascular smooth muscle cells. Circulation 104(12):1399-406, 2001. e-Pub 2001. PMID: 11560856.
121. Wang Y, Liu J, Wu Y, Luo W, Lin SH, Lin H, Hawk N, Sun T, Guo JQ, Estrov Z, Talpaz M, Champlin R, Arlinghaus RB. Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death. Cancer Res 61(1):138-44, 2001. e-Pub 2001. PMID: 11196151.
122. Wu Y, Ma G, Lu D, Lin F, Xu HJ, Liu J, Arlinghaus RB. Bcr: a negative regulator of the Bcr-Abl oncoprotein. Oncogene 18(31):44164-24, 1999. e-Pub 1999. PMID: 10442632.
123. Chen G, Yuan SS, Liu W, Xu Y, Trujillo K, Song B, Cong F, Goff SP, Wu Y, Arlinghaus R, Baltimore D, Gasser PJ, Park MS, Sung P, Lee EY. Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J Biol Chem 274(18):12748-12752, 1999. e-Pub 1999. PMID: 10212258.
124. Guo XY, Cuillerot JM, Wang T, Wu Y, Arlinghaus R, Claxton D, Bachier C, Greenberger J, Colombowala I, Deisseroth AB. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells. Oncogene 17(7):825-33, 1998. e-Pub 1998. PMID: 9779999.
125. Wu Y, Liu J, Arlinghaus RB. Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase. Oncogene 16(1):141-46, 1998. e-Pub 1998. PMID: 9467953.
126. Ma G, Lu D, Wu Y, Liu J, Arlinghaus RB. Bcr phosphorylated on tyrosine 177 binds Grb2. Oncogene 14(19):2367-72, 1997. e-Pub 1997. PMID: 9178913.
127. Liu J, Wu Y, RB A. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein. Cancer Res 56(22):5120-4, 1996. e-Pub 1996. PMID: 8912843.
128. Liu J, Wu Y, Ma GZ, Lu D, Haataja L, Heisterkamp N, Groffen J, Arlinghaus RB. Inhibition of Bcr serine kinase by tyrosine phosphorylation. Mol Cell Biol 16(3):998-1005, 1996. e-Pub 1996. PMID: 8622703.
129. Salem A, Wu Y, Albarracin CT, Middleton LP, Kalhor N, Peng Y, Huang X, Aung PP, Chen H, Sahin AA, Ding QQ. A Comparative Evaluation of TRPS1 and GATA3 in Adenoid Cystic, Secretory, and Acinic Cell Carcinomas of the Breast and Salivary Gland. Hum Pathol.
130. Marques-Piubelli ML, Lyapichev KL, Aakash FNU, Adrada B, Stewart J, Hunt KK, Clemens MK, Iyer S, Wu Y, El Hussein S, Xu J, Ok CY, Li S, Ferrufino-Schmidt MC, Nahmod K, Yoga A, Hunsicker L, Evans MG, Resetkova E, Qiu L, Khanlari M, Garces SA, Bueso-Ramos CE, Medeiros LJ, Miranda RN. The Spectrum of Non-neoplastic Changes Associated with Breast Implants: Histopathology, Imaging and Clinical Significance. Am J Surg Pathol.
131. Sun H, Kang EY, Chen H, Sweeney KJ, Suchko M, Wu Y, Wen J, Krishnamurthy S, Albarracin CT, Ding QQ, Foo WC, Sahin AA. Immunohistochemical Assessment of HER2 Low Breast Cancer: Interobserver Reproducibility and Correlation with Digital Image Analysis. Breast Cancer Res Treat.

Invited Articles

1. Tang F, Wu Y. [Pathologic evaluation of breast cancer specimens after neoadjuvant chemotherapy]. Zhonghua Bing Li Xue Za Zhi 38(1):8-12, 2009. e-Pub 2009. PMID: 19489218.

Review Articles

1. Yang L, Lin H, Shen Y, Roy M, Albarracin C, Ding Q, Huo L, Chen H, Wei B, Bu H, Bedrosian I, Wu Y. Clinical outcome and therapeutic impact on neuroendocrine neoplasms of the breast: a national cancer database study. Breast Cancer Res Treat 202(1):23-32, 2023. e-Pub 2023. PMID: 37566192.
2. Han Y, Wang J, Wu Y, Xu H, Wang Y, Xu B. Optimal Choice as First-Line Therapy for Patients with Triple-Negative Breast Cancer: A Bayesian Network Meta-Analysis. Curr Oncol 29(12):9172-9180, 2022. e-Pub 2022. PMID: 36547132.
3. Liu M, Li X, Li Y, Wang Z, Cheng L, Song X, Wu Y. Rosai-Dorfman disease with features of IgG4-related disease in the breast: Cases report and literature review. Asian Pac J Allergy Immunol 36(1):51-57, 2018. e-Pub 2018. PMID: 28577522.
4. Adrada B, Wu Y, Yang W. Hyperechoic lesions of the breast: radiologic-histopathologic correlation. AJR Am J Roentgenol 200(5):W518-30, 2013. e-Pub 2013. PMID: 23617519.
5. Leng X, Wu Y, Arlinghaus RB. Relationships of lipocalin 2 with breast tumorigenesis and metastasis. J Cell Physiol 226(2):309-14, 2011. e-Pub 2011. PMID: 20857428.
6. Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF. Molecular classification of breast cancer: limitations and potential. Oncologist 11(8):868-77, 2006. e-Pub 2006. PMID: 16951390.

Other Articles

1. Wan, L, Xu, K, Wei, Y, Zhang, J, Han, T, Fry, C, Zhang, Z, Wang, YV, Huang, L, Yuan, M, Xia, W, Chang, W, Huang, WC, Liu, CL, Chang, YC, Liu, J, Wu, Y, Jin, VX, Dai, X, Guo, J, Liu, J, Jiang, S, Li, J, Asara, JM, Brown, M, Hung, M, Wei, W Erratum. Molecular cell 85(15):3002, 2025. PMID: 40706598.

Editorials

1. Wu Y. Commentary: Intraoperative assessment of breast cancer specimens decreases cost and number of reoperations. Breast Diseases: A Year Book Quarterly 23(1):59-60, 2012.

Abstracts

1. Ye Q, Klippel D, Albarracin C, Chen H, Contreras A, Ding Q, Huo L, Khazai L, Middleton L, Resetkova E, Sahin A, Sun H, Sweeney K, Symmans W, Wu Y, Krishnamurthy S. A Prospective Study of Real Time Whole Slide Imaging of Frozen Sections for Intraoperative Evaluation of Axillary Sentinel Lymph Nodes in Breast Cancer. Mod Pathol 104(3):S321-22, 2024. e-Pub 2024.
2. Sun H, Huo L, Sweeney K, Resetkova E, Chai D, Chen H, Albarracin C, Wu Y, Ding Q. SMARCA4/BRG1 Deficiency in Breast Carcinoma by Immunohistochemistry Study. Mod Pathol 104(3):S274-75, 2024. e-Pub 2024.
3. Albarracin, CT, Wen J, Sweeney KJ, Ding Q, Wu Y. Concordance of Nottingham histologic and neuroendocrine grading schemes in mammary neuroendocrine neoplasms. 35th European Congress of Pathology, 2023. e-Pub 2023.
4. Wu Y, Mersereau M, Chen H, Albarracin CT. Ki67 quantitation in breast cancer: a comparative analysis of four counting methods. 35th European Congress of Pathology, 2023. e-Pub 2023.
5. E-Y K, Chen H, Sweeney KJ, Suchko M, Wu Y, Wen J, Krishnamurthy S, Albarracin CT, Ding Q, Foo WC, Sahin AA. Immunohistochemical Assessment of HER2-Low Breast Cancer: Interobserver Reproducibility and Correlation with Digital Image Analysis. Laboratory Investigation 103(3):S1720, 2023. e-Pub 2023.
6. Chen H, Wu Y, Ding Q, Huo L, Khazai L, Sahin AA, Albarracin CT. HER2-low Breast Cancers: Comparison of HER2 Scores by Immunohistochemistry and Oncotype DX. Laboratory Investigation 103(3):S114, 2023. e-Pub 2023.
7. Ye Q, Liu A, Estrella J, Kalhor N, Albarracin CT, Ding Q, Wu Y. TRPS1 Expression in Neuroendocrine Neoplasms of Breast and Other Organs. Laboratory Investigation 103(3):S237, 2023. e-Pub 2023.
8. Salem A, Han C, Wu Y, Albarracin CT, Middleton LM, Chen H, Sahin AA, Ding Q. A Comparative Evaluation of TRPS1 and GATA3 in Adenoid Cystic, Acinic Cell, and Secretory Carcinomas of the Breast and Salivary Glands. Laboratory Investigation 103(3):S206-S207, 2023. e-Pub 2023.
9. Salem A, Wu Y, Ding Q, Middleton LP. Prognostic Impact of NOTCH1 Expression in Primary Breast Adenoid Cystic Carcinoma. Laboratory Investigation 103(3):S207-S208, 2023. e-Pub 2023.
10. Salem A, Chen H, Albarracin C, Wu Y, Sneige N, Khazai L, Ding QQ, Tang ZY, Sahin A, Yoon E. Correlation amongst Immunohistochemical (IHC) Scores, Fluorescence In Situ Hybridization (FISH) Groups and Final HER2 Status on Breast carcinoma (BC) and Quality Issues Surrounding Indeterminate FISH Tests: A Single Center Experience. Modern Pathology 35(Suppl 2):1384-1385, 2022. e-Pub 2022.
11. Sweeney K, Wang J, Albarracin C, Roy-Chowdhuri S, Patel K, Routbort M, Ding Q, Wu Y, Huo L, Sahin A, Luthra R, Chen H. PTEN Alterations in Advanced ER plus Breast Cancer: Correlation with Clinicopathologic and Molecular Features. Modern Pathology 35(Suppl 2):198-199, 2022. e-Pub 2022.
12. Yoon, Wang E, Wu G, Y, Chen, Albarracin H, Resetkova C, Krishnamurthy E, Salisbury S, Sahin T, Ding A, Q Q. Expression of TRPS1, SOX10 and GATA3 in Triple Negative Invasive Ductal and Lobular Carcinomas. Modern Pathology 35(Suppl 2):216-217, 2022. e-Pub 2022.
13. Chen H, Hou TY, Hou L, Wu Y, Wang WL, Albarracin C. Significance of ER-/PR plus Breast Cancer Cases: Re-evaluation of Biomarkers Status and Clinical Correlates. Modern Pathology 33((Suppl. 2)):1848, 2021. e-Pub 2021.
14. Huang X, Ding Q, Guo H, Sui D, Gong Y, Wu Y, Chen H, Wang WL, Huo L. Comparison of Three FDA Approved PD-L1 Immunohistochemistry Assays in Triple Negative Breast Carcinoma. Modern Pathology 33((Suppl. 2)):182, 2020. e-Pub 2020.
15. Yang L, Roy M, Albarracin C, Huo L, Bedrosian I, Bu H, Wu Y. Neuroendocrine Neoplasms (NENs) of the Breast Have Poorer Prognosis then Invasive Carcinoma of No Special Type (NST) (**Primary mentor for trainee**). Modern Pathology 33((Suppl. 2)):189, 2020. e-Pub 2020.
16. Wang J, Chen H, Koenig J, Bedrosian I, Wu Y, Albarracin C. Discordance of Oncotype DX Scores in Bilateral and Unilateral Multifocal Breast Cancers. Modern Pathology 33((Suppl. 2)):279, 2020. e-Pub 2020.
17. McLemore LE, Albarracin C, Gruschkus SK, Dhamne S, Basset Jr S, Wu Y, Yim I, k L, Chen H. HER2 Testing in Breast Cancers: Comparison of Assays and Interpretation Using ASCO-CAP 2013 with 2018 Guidelines. Modern Pathology 33((Suppl. 2)):99, 2019. e-Pub 2019.
18. McLemore LE, Chen H, Dhamne S, Basset Jr S, Gruschkus SK, Wu Y, Yim I, Lin K, Albarracin C. Estrogen receptor immunohistochemical staining versus Oncotype DX: Clinicopathologic characteristics and recurrence scores of concordant and discordant cases. Modern Pathology 33((Suppl. 2)):100-101, 2019. e-Pub 2019.
19. Yang F, Song J, Mino B, Parra ER, Sahin AA, Wistuba II, Litton J, Mittendorf EA, Wu Y. Increased PD-L1 Expression in HER2-Positive Breast Cancer without Pathologic Complete Response to Neoadjuvant Therapy. 107th Annual Meeting, United States and Canadian Academy of Pathology, Vancouver, British Columbia, Canada, 2018. e-Pub 2018.
20. Albarracin C, Trinidad CM, Song J, Ward K, Dhamne S, Rosen D, Wu Y, Chen H, Baghaki HS, Barrera AMG, Arun B. Androgen Receptor Expression In BRCA-Associated Breast Cancers. Modern Pathology 31((Suppl. 2)):44, 2018. e-Pub 2018.
21. Guo H, Ding Q, Gong Y, Gilcrease MZ, Zhao M, Zhao J, Wu Y, Chen H, Moulder S, Wang W, Huo L. PD-L1 Expression 9clone 22C3) and Tumor Infiltrating Lymphocytes (TIL) in Primary Breast Cancer. Modern Pathology 31((Suppl. 2)):65-65, 2018. e-Pub 2018.
22. Guo H, Ding Q, Gong Y, Gilcrease MZ, Zhao M, Zhao J, Wu Y, Chen H, Moulder S, Wang W, Huo L. PD-L1 Expression (clone 28-8) and Tumor Infiltrating Lymphocytces (TIL) in Primary Breast Cancer. Modern Pathology 31((Suppl. 2)):65-66, 2018. e-Pub 2018.
23. Rauch GM, Zhu H, Li H, Adrada B, Santiago L, Candelaria RP, Wang H, Leung J, Thompson A, Litton J, Wu Y, Lim B, Moulder S, Mittendorf EA, Yang W. Quantitative MRI features analysis for differentiation of triple negative and HER2 positive subtypes of breast cancer. San Antonio Breast Cancer Symposium, San Antonio, TX, 2017. e-Pub 2017.
24. Rauch GM, Zhu H, Li H, Adrada B, Santiago L, Candelaria RP, Wang H, Leung J, Litton J, Murthy R, Wu Y. Association of Quantitative MRI Features Analysis with Tumor infiltrating Lymphocytes. Treatment Response Prediction in HER2 Positive Subtypes of Breast Cancer. San Antonio Breast Cancer Symposium, San Antonio, TX, 2017. e-Pub 2017.
25. He J, Zhang Z, Chen S, Motiee A, Zhang Y, Zhao S, Wang J, Albarracin CT, Abraham SC, Wu Y. Novel Herceptin-Based IHC Test Detects HER2+ Breast Cancers Correlating to Responses to HER2 Targeted Therapy. 106 Annual Meeting, United States and Canadian Academy of Pathology, San Antonio, TX, 2017. e-Pub 2017.
26. Yang F, Rodriguez-Canales J, Mino Mittendorf EA, Sahin AA, Wu Y. Immune Profiling of HER2 Positive TILS Rich Breast Cancer: Correlation with Response to Neoadjuvant Therapy. 106th Annual Meeting, United States and Canadian Academy of Pathology, San Antonio, TX, 2017. e-Pub 2017.
27. Li Y, Luthra R, Hu J, Shen L, Broaddus RR, Resetkova E, Wu Y, Albarracin CT. mir-182*. mir-183 and mir-143 Are Deregulated in Endometrial Endometroid Cancer. 106th Annual Meeting United States and Canadian Academy of Pathology, San Antonio, TX, 2017. e-Pub 2017.
28. Vasa P, Mittendorf EA, Wang X, Hunt KK, Wu Y, Sahin A. Prognostic Value of Ki-67 Expression in Her-2 Positive Breast Cancer After Primary Systemic Therapy. CAP 16, Las Vegas, 2016. e-Pub 2016.
29. Yang F, Swisher S, Mittendorf EA, Lyons GR, Tapia C, Wang X, Bassett RL, Hunt KK, Sahin AA, Wu Y. Evaluation of Histopathologic Features That Affect Interobserver Agreement on Tumor Infiltrating Lymphocyte (TIL) Quantities in Breast Cancer. 105th Annual Meeting, United States and Canadian Academy of Pathology, Seattle, WA, 2016. e-Pub 2016.
30. Ding Q, Mittendorf EA, Lyons, GR, Bassette Jr R, Hunt KK, Sahin AA, Wu Y. Cliniopathologic Features in Predicting Complete Pathologic Response (pCR) After Neoadjuvant Herceptin Chemotherapy in HER2+ Breast Cancers. United States and Canadian Academy of Pathology Annual Meeting, 2016. e-Pub 2016.
31. Andrews C, Mittendorf EA, Song J, Hunt KK, Sahin AA, Wu Y. Tumor Infiltrating Lymphocytes (TIL) in Predicting Neoadjuvant Therapy Response and Survival in HER2+ Breast Cancers. United States and Canadian Academy of Pathology Annual Meeting, 2016. e-Pub 2016.
32. Dhamne S, Arun B, Ward K, Wu Y, Rosen DG, Cui X, Resetkova E, Duan X, Chen H, Bedrosian I, Gutierrez Barrera A, Albarracin CT. BRCA1 and BRCA2-Associated Breast Cancers Demonstrate Distinct Histopathologic Features, Biomarker Expression Patterns and Molecular Subtypes. United States and Canadian Academy of Pathology Annual Meeting, 2016. e-Pub 2016.
33. Albarracin C, Dhamn S, Arun, Ward K, Wu Y Rosen D, Cui XY, Resetkova E, Duan XZ, Chen H, Bedrosian I, Barrera AG. BRCA-1 and BRCA2-Associated Breast Cancers Demonstrate Distinct Histopathologic Features, Biomarker Expression Patterns and Molecular Subtypes. Modern Pathology 29:39a-39a, 2016. e-Pub 2016.
34. Swisher S, Wu Y Castaneda C, Lyons G, Yang F, Tapia C, Wang X, Bassett R, Castillo M, Casavilca S, Hunt KK, Sahin A, Mittendorf EA. Interobserver agreement for assessment of tumor infiltrating lymphocytes (TIL) in breast cancer. Annals of Surgical Oncology 23([Abstract P43]):S60, 2016. e-Pub 2016.
35. Zhou P, Abraham SC, Albarracin CT, Wu Y. Metastastic Neoplasm to the Breast: Study of 210 Cases. United States and Canadian Academy of Pathology 2015 Annual Meeting, Boston, MA, 2015. e-Pub 2015.
36. Castaneda Altamirano C, Mittendorf EA, Ezcurra PA, Casavilca Zambrano S, Nunez Butron MT, Wu Y, Castillo Garcia M, Rojas KI, Billagas Bernaola V, Belmar Lopez C, Cerna KD, Gomez HL, Abugattas JE, Cotrina JM, Gonzalez-Angulo AM, Vidaurre T. Comprehensive analysis of variation of tumor infiltrating lymphocytes during neoadjuvant chemotherapy in triple-negative breast cancer. Journal of Clinical Oncology (#3035)(33(suppl)), 2015. e-Pub 2015.
37. Mittendorf EA, Wang C, Yua P, Roman K, Wu Y, Alatrash G, Hoyt C. Multispectral imaging allows visualization and quantification of multiple immunologic cell types in breast tumor tissues. 38th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, 2014. e-Pub 2014.
38. Liang Y, Li X, Wang J, Huo L, Albarracin CT, Gong Y, Wu Y. Prognostic Significance of Multifocal Lesion in ER+ Breast Cancers. United States and Canadian Academy of Pathology 2014 Annual Meeting, 2014. e-Pub 2014.
39. Duan X, Gullet A, Sneige N, Rosen D, Resetkova E, Ersahin C, Wu Y, Bedrosian I, Albarracin CT. Clinicopathologic features of male paget disease of breast: 11 cases from a single institution. Mod Pathol 26(Suppl 2): 37A(37A), 2013. e-Pub 2013.
40. Barina A, Arun B, Sneige N, Gutierrez-Barriers AM, Rosen D, Abrahams S, Resetkova E, Wu Y, Albarracin CT. Histology of Breast Cancer in Patients with Lynch Syndrome. United States and Canadian Academy of Pathology. 2013 Annual Meeting, Baltimore, MD, 2013, 2013. e-Pub 2013.
41. Duan X, Gullet A, Sneige N, Resetkova E, Ersahin C, Wu Y, Bedrosian I, Albarracin CT. Male mammary Paget disease: Ten cases from a single institution. Virch Arch 463(Suppl): PS-17-090, 2013(PS-17-090), 2013. e-Pub 2013.
42. Aquil B, Arun B, Sneige N, Barrera-Guttierez AM, Rosen D, Abrahams S, Resetkova E, Wu Y, Albarracin CT. Histology of breast cancer in patients with Lynch Syndrome. Mod Pathol 26(Suppl 2): 27A, 2013(27A), 2013. e-Pub 2013.
43. Zhu X, Chen J, Xing Y, Albarracin CT, Zhao Y, Rao P, Li X, Bell D, El-Naggar A, Abraham S, Wu Y. Adenoid Cystic Carcinoma of the Breast: Clinicopathologic and Molecular Analysis of 56 Cases. United States and Canadian Academy of Pathology, 2012 Annual Meeting, Vancouver, BC, 2012. e-Pub 2012.
44. Gullett AE, Sneige N, Prieto VG, Kelly CM, Bassett RL, Resetkove E, Duan X, Li Y, Rosen D, Wu Y, Huo L, Klein K, Bedrosian I, Arun B, Hunt K, Albarracin CT. Pathological and Clinical Characteristics of Mammary Paget Disease: 25-Year Experience from Major Tertiary Referral Center. United States and Canadian Academy of Pathology 2012. Annual Meeting, Vancouver, BC, Canada, 2012, 2012. e-Pub 2012.
45. Albarracin CT, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Y <, Gilcrease MZ, Bedrosian I, Dawood S, Arun B, and Duan X. Clinicopathological Features of Invasive Paget Disease of Breast: Experience from a Single Institution. International Academy of Pathology Cape Town, South Africa, 2012, 2012. e-Pub 2012.
46. Liu H, Li D, Tang X, Wistuba I, Sahin AA, Mittendorf EA, Abraham SC, Wu Y. EGFR gene amplification in invasive breast cancers. International Academy of Pathology Cape Town, South Africa, 2012, 2012. e-Pub 2012.
47. Gong Y, Chen J, Radvanyi L, Rosen DG, Wu Y. Expression of Enhancer of Zeste homolog 2 (EZH2) in Invasive Neuroendocrine Carcinoma of the Breast. International Academy of Pathology, Cape Town, South Africa, 2012, 2012. e-Pub 2012.
48. Dallas NA, Yi M, Hunt KK, Shah RR, Kuerer HM, Litton JK, Wu Y, Caudle AS, Meric-Bernstam F, Sahin AA, Mittendorf EA. Evaluation of the stage IB designation of the 7th edition of the AJCC staging system. J Clin Oncol Suppl (#1130), 2012. e-Pub 2012.
49. Le DF, Wu Y, Spizzo R, Yoo SY, Mao M, Wang J, Calin GA, Bast, Jr BC. HER2-targeted antibody upregulates miRNA-194 and downregulates profilin 2 and DNMT3A in HER2-positive breast cancer. AACR 102nd Annual Meeting. Orlando, FL, 2011. e-Pub 2011.
50. Nayak A, Krishnamurthy S, Wu Y, Gilcrease MZ. Squamous Carcinoma of the Breast: A Cliniopathologic Study of 21 Cases. United States and Canadian Academy of Pathology, The 100th Annual Meeting, San Antonio, Texas. Mod Pathol 24(Suppl 1):56A (#225), 2011. e-Pub 2011.
51. Symmans WF, Hatzis C, Valero V, Booser DJ, Esserman L, Martin M, Vidaurre T, Holmes F, Souchon EA, Lluch A, Cotrina J, Gomez H, Hubbard R, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Pusztai L A. Genomic Predictor of Survival Following Taxane-Anthracycline Chemotherapy for Breast Cancer. 33rd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, 2010. e-Pub 2010.
52. Chen JQ, Litton J, Xiao L, H-Z Z, Warneke CL, Wu Y, Shen X, Sahin A, Katz R, Murray JL, Radvanyi L. Quantitative Immunohistochemical Analysis and Prognostic Significance of TRPS-1, a New GATA Transcription Factor Family Member, in Breast Cancer. 33rd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, 2010. e-Pub 2010.
53. Bao Y, Chen JQ, Wu Y, X-H L, Wang E, Marincola F, Radvanyi LG. TRPS-1, a New GATA Family Transcription Factor, Regulates Epithelial-Mesenchymal Transition and Maintains an Estrogen Responsive, Claudin-Positive Phenotype in Breast Cancer Cells. 33rd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, 2010. e-Pub 2010.
54. Le XF, Spizzo R, Mao M, Wu Y, Calin GA, Jr BB. DNA Cytosine-5-Methyltransferase 3A (DNMT3A) is a Direct Target of miRNA-194 in Breast Cancer Cells. AACR 101st Annual Meeting, Washington DC, 2010. e-Pub 2010.
55. Wei B, Tian Z Tang F, Wei W, GIlcrease MZ, Huo L, Abarracin CT, Resetkova E, Middleton LP, Sahin A, Chen J, Abraham SC, Wu Y. Prognostic Factors of Primary Invasive Mammary Neuroendocrine Carcinoma: Clinicopathologic Analysis of 74 Cases. United States and Canadian Academy of Pathology, The 99th Annual Meeting, Washington DC. Mod Pathol 23(Suppl 1):77A(#336), 2010. e-Pub 2010.
56. Gullett AE, Prieto VG, Lopez A, Klein K, Arun B, Bedrosian I, Resetkova E, Wu Y, Sneige N, Albarracin CT. Type of Mammary Paget Disease is Associated with Disease Free Survival. United States and Canadian Academy of Pathology, The 99th Annual Meeting, Washington DC. Mod Pathol 23(Suppl 1):115A(#507), 2010. e-Pub 2010.
57. Leng X, Shui R, Shen L, Baggerly KA, Liu X, Liu C, Sahin A, Abraham SC, Wu Y. High Resolution Analysis of Genome-Wide Copy Number Change in Neuroendocrine Carcinoma of the Breast. United States and Canadian Academy of Pathology, The 99th Annual Meeting, Washington DC. Mod Pathol 23(Suppl 1):425A(#1898), 2010. e-Pub 2010.
58. Ding T, Leng X, Lin H, Lin F, Zen B, Symmans WF, Yan K, Pusztai L, Arlinghaus RB, Wu Y. Blocking Lipocalin 2 function impairs mammary tumor formation and lung metastasis. United States and Canadian Academy of Pathology, The 98th Annual Meeting, Boston, MA. Mod Pathol 22(Suppl 1):338A(#1533), 2009. e-Pub 2009.
59. Gullett AE, Duan X, Fuller GN, Brown R, Li Y, Luthra R, Wiseman W, Resetkova E, Yao H, Puduvalli V, Wu Y, Bruner J, Albarracin CT. Expression of annexin A1 and constitutive with S phase kinase-associated protein (Spr2) in glioma progression. United States and Canadian Academy, The 98th Annual Meeting, Boston, MA. Mod Pathol 22(Suppl 1):329A(#1492), 2009. e-Pub 2009.
60. Liedtke C, Yan K, Wu Y, Hortobagyi GN, Symmans WF, Valero V, Gotte M, Kiesel L, Pusztai L. Targeting of breast cancer with non-oncology drugs-possible novel therapeutic option for triple-negative breast cancer. San Antonio Breast Cancer Symposium 30th Annual Meeting, 2008. e-Pub 2008.
61. Mittendorf EA, Esteva FJ, Meric-Bernstam F, Hunt KK, Wu Y, Buzdar A, Dawood S, Hortobagyi GN, Gonzalez-Angulo AM. Determination of HER2 status in patients achieving less than a pCR following neoadjuvant therapy with combination chemotherapy plus Trastuzumab. American Society of Clinical Oncology, 2008. e-Pub 2008.
62. Tang F, Gilcrease MZ, Albarracin CT, Huo L, Middleton LP, Resetkova E, Wu Y. Invasive solid papillary carcinoma of the breast: a clinicopathologic analysis of 52 cases. United States and Canadian Academy of Pathology, The 97th Annual Meeting, Denver, CO. Mod Pathol 21(Suppl 1):56A(#248), 2008. e-Pub 2008.
63. Downs-Kelly E, Nayeemuddin KM, Albarracin C, Wu Y, Hunt KK, Gilcrease MZ. Matrix-producing carcinoma of the breast: clinicopathologic features associated with locoregional recurrence and survival. United States and Canadian Academy of Pathology, The 97th Annual Meeting, Denver, CO. Mod Pathol 21(Suppl 1):29A(#120), 2008. e-Pub 2008.
64. Nicolas MM, Wu Y, Middleton LP, Gilcrease MZ. Loss of myoepithelium and laminin at the tumor-stromal interface in circumscribed solid papillary carcinoma of the breast. United States and Canadian Academy of Pathology, The 96th Annual Meeting, San Diego, CA. Mod Pathol 20(Suppl 2):43A(#176), 2007. e-Pub 2007.
65. Khalifeh I, Albarracin CT, Wu Y, Sneige N. Clinical, histopathologic, and biologic/molecular features of microglandular adenosis with transitions into in-situ and invasive carcinoma. United States and Canadian Academy of Pathology, The 96th Annual Meeting, San Diego, CA. Mod Pathol 20(Suppl 2):38A(#152), 2007. e-Pub 2007.
66. Liao Y, Wu Y, Ping B, Wei Y, Donehower LA, Hung MC. Chemosensitization by targeting a protein phosphatase in human cancer cells. The 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer. Therapeutics. Prague, Czech Republic, 2006. e-Pub 2006.
67. Edelweiss M, Rosen DG, Garcia MKP, Wu Y, Liu J, Albarracin C. Estrogen and androgen receptors expression in primary breast carcinoma, axillary lymph node metastasis and distant metastasis. The Endocrine Society’s 88th Annual Meeting, Boston, MA, 2006. e-Pub 2006.
68. Lin H, Anderson K, Rouzier R, Gong Y, Pusztai L, Symmans WF, Arlinghaus RB, Wu Y. Neutrophil gelatinase-associated lipocalin (NGAL) is highly associated with HER2+/ER-breast cancers and is a downstream effector of P13/AKT pathway. United States and Canadian Academy of Pathology, The 95th Annual Meeting, Atlanta, GA. Mod Pathol 19(Suppl 1):33A(#139), 2006. e-Pub 2006.
69. Gullet AE, Fuller GN, Wu Y, Bruner JM, Albarracin CT. Increased annexin A1 expression in high-grade diffuse gliomas: a potential prognostic marker. United States and Canadian Academy of Pathology, The 95th Annual Meeting, Atlanta, GA. Mod Pathol 19(Suppl 1):285A(#1325), 2006. e-Pub 2006.
70. Huo L, Wu Y, Meric-Bernstam F, Sahin AA. Morphologic features of ipsilateral recurrent breast cancers in patients treated with breast conserving therapy (BCT). United States and Canadian Academy of Pathology, The 94th Annual Meeting, San Antonio, TX, 2005. e-Pub 2005.
71. Huo L, Wu Y, Meric-Bernstam F, Sahin AA. Morphologic features of ipsilateral recurrent breast cancers in patients treated with breast conserving therapy (BCT). United States and Canadian Academy of Pathology, The 94th annual meeting, San Antonio, TX. Mod Pathol 18(Suppl 1):36A(#153), 2005. e-Pub 2005.
72. Loggie BW, Wu Y, Saboorian MH, Kabbani W, Fleming J, Frawley WH, Ashfaq R. COX-2 and thymidylase synthase correlate with proliferative rates of mucinous tumors with diffuse peritoneal dissemination. American Society of Clinical Oncology, The 38th Annual Meeting, Orlando, FL, 2002. e-Pub 2002.

Book Chapters

1. Wu, Y, Shin, SJ, Sahin, AA. Special Histologic Types and Special Morphologic Patterns of Invasive Ductal Carcinoma of No Special Type, 575-614, 2022.
2. Wu Y, Chen H, Sahin AA. Molecular Classification and Testing of Breast Carcinoma. In: Rosen's Breast Tumors, 5th Edition. Lippincott Williams & Williams, 2020.
3. Sapino A, Rakha EA, Hironobu S, Reis-Filho J, Wu Y. Neuroendocrine Neoplasms. In: WHO Classifications of Tumors-Breast Tumors, 5th Edition. IARC, 2019.
4. Wu Y, Shin SJ, Sahin AA. Special Histologic Types of Breast Cancer. In: A Comprehensive Guide to Core Needle Biopsies of the Breast. Springer, 2016.
5. Wu Y, and Sahin AA. Prognostic and Predictive Factors of Invasive Breast Cancer. In: In Breast Disease: Diagnosis and Pathology. Ed(s) Aydiner A, Igci A, Soran A. Springer, 2015.
6. Wu Y, Sahin AA. Molecular Classification and Testing of Breast Carcinoma. In: Rosen's Breast Pathology. 4th. Lippincott, Williams & Wilkins, 2014.
7. Wu Y. Pathologic Evaluation of Invasive Breast Cancer. In: Advanced Therapy of Breast Disease. 3rd. People’s Medical Publishing House, 2012.

Letters to the Editor

1. Albarracin C, Edgerton ME, Gilcrease MZ, Huo L, Krishnamurthy S, Middleton LP, Resetkova E, Sahin AA, Sneige N, Fraser WS, Wu Y. Is it too soon to start reporting HER2 genetic heterogeneity?. Arch Pathol Lab Med 134: 162-3, 2010.

Patents

1. BCR-ABL Directed Compositions and Uses for Inhibiting Philadelphia Chromosome Stimulated Cell Growth. Patent Number: US 6,537,804 B1.